NUREXONE BIOLOGIC INC. (J90) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NUREXONE BIOLOGIC INC. (J90) has a cash flow conversion efficiency ratio of -0.426x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.17 Million ≈ $-1.37 Million USD) by net assets (€2.76 Million ≈ $3.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is NUREXONE BIOLOGIC INC.'s balance sheet to measure how much of total assets are equity-financed.
NUREXONE BIOLOGIC INC. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how NUREXONE BIOLOGIC INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore NUREXONE BIOLOGIC INC. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
NUREXONE BIOLOGIC INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NUREXONE BIOLOGIC INC. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Atlantaa Limited
NSE:ATLANTAA
|
-0.073x |
|
Drax Group PLC
LSE:DRX
|
0.144x |
|
CItech Co Ltd
KO:004920
|
-0.026x |
|
Live Ventures Inc
NASDAQ:LIVE
|
0.103x |
|
INFAC Corporation
KO:023810
|
-0.191x |
|
Elektrocieplownia Bedzin
WAR:BDZ
|
0.159x |
|
Eurotel SA
WAR:ETL
|
0.124x |
|
Deliveroo Holdings PLC
LSE:ROO
|
0.239x |
Annual Cash Flow Conversion Efficiency for NUREXONE BIOLOGIC INC. (2021–2025)
The table below shows the annual cash flow conversion efficiency of NUREXONE BIOLOGIC INC. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see J90 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €2.76 Million ≈ $3.22 Million |
€-4.51 Million ≈ $-5.27 Million |
-1.636x | +41.07% |
| 2024-12-31 | €1.76 Million ≈ $2.06 Million |
€-4.89 Million ≈ $-5.71 Million |
-2.776x | +82.16% |
| 2023-12-31 | €189.00K ≈ $220.96K |
€-2.94 Million ≈ $-3.44 Million |
-15.561x | -747.60% |
| 2022-12-31 | €2.10 Million ≈ $2.45 Million |
€-3.85 Million ≈ $-4.50 Million |
-1.836x | -75.39% |
| 2021-12-31 | €1.18 Million ≈ $1.38 Million |
€-1.23 Million ≈ $-1.44 Million |
-1.047x | -- |
About NUREXONE BIOLOGIC INC.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of p… Read more